I am a
Home I AM A Search Login

Papers of the Week

2021 Jul 27

Clin Gastroenterol Hepatol

Hepatic Fat Reduction Due to Resmetirom in Patients with Nonalcoholic Steatohepatitis Is Associated With Improvement of Quality of Life.


Younossi ZM, Stepanova M, Taub RA, Barbone J M, Harrison SA
Clin Gastroenterol Hepatol. 2021 Jul 27.
PMID: 34329774.


Nonalcoholic steatohepatitis (NASH) is a chronic liver disease associated with adverse clinical outcomes and impaired health-related quality of life (HRQL).